Anesth Analg:术后并发症影响普通手术患者心脏骤停后的生存率

2017-11-15 李华宇 “罂粟花”微信号

普通手术患者术后心脏骤停罕见但却与其死亡率高度相关,且往往伴有术后并发症。而普通手术患者心脏骤停之前的并发症与心脏骤停之后的死亡率之间的关系尚未得到完全证实。

背景与目的:普通手术患者术后心脏骤停罕见但却与其死亡率高度相关,且往往伴有术后并发症。而普通手术患者心脏骤停之前的并发症与心脏骤停之后的死亡率之间的关系尚未得到完全证实。

方  法:通过2012-2013年美国外科学会全国外科质量改进计划获得了术后日(POD)#0(至POD#30)发生心脏骤停患者的数据,并对其进行回顾观察性研究,前期并发症定义为以下至少有一种发生在心脏骤停之前:(1)急性肾损伤; (2)急性呼吸衰竭; (3)深静脉血栓形成/肺栓塞; (4)心肌梗死; (5)败血症/败血性休克; (6)中风; 和/或(7)输血。采用Cox比例风险模型进行评估心脏骤停之前的并发症和心脏骤停之后的死亡率之间的关系以对术前危险因素进行调整。

结  果: 在1352例术后发生心脏骤停的患者中,746例(55%)发生心脏骤停前至少有1例并发症。 30天内总死亡率为71%(958/1352),且前期有无并发症患者的死亡率相似(71%[533/746] vs 70%[425/606]; P = .60)。 经调整后的Cox模型(风险比为1.03; 95%置信区间,0.90-1.18; P = .70),与前期无并发症的患者相比,前期有并发症患者的死亡率并没有增加。 此外,前期并发症并未与个别分析中死亡率的增加有关。

结  论:在POD#0且发生心脏骤停的普通手术患者中,心脏骤停前的并发症常见但却与心脏骤停之后的死亡率增加无关。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633409, encodeId=1065163340943, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Sep 30 21:26:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050925, encodeId=2af92050925e5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 17 12:26:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700043, encodeId=7b341e0004365, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Thu Apr 12 16:26:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757892, encodeId=d3db1e5789297, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 27 09:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256612, encodeId=3d1d1256612ba, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 17 01:26:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-09-30 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633409, encodeId=1065163340943, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Sep 30 21:26:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050925, encodeId=2af92050925e5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 17 12:26:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700043, encodeId=7b341e0004365, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Thu Apr 12 16:26:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757892, encodeId=d3db1e5789297, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 27 09:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256612, encodeId=3d1d1256612ba, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 17 01:26:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633409, encodeId=1065163340943, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Sep 30 21:26:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050925, encodeId=2af92050925e5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 17 12:26:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700043, encodeId=7b341e0004365, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Thu Apr 12 16:26:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757892, encodeId=d3db1e5789297, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 27 09:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256612, encodeId=3d1d1256612ba, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 17 01:26:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-04-12 经常头晕
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633409, encodeId=1065163340943, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Sep 30 21:26:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050925, encodeId=2af92050925e5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 17 12:26:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700043, encodeId=7b341e0004365, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Thu Apr 12 16:26:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757892, encodeId=d3db1e5789297, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 27 09:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256612, encodeId=3d1d1256612ba, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 17 01:26:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2018-08-27 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=1633409, encodeId=1065163340943, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Sep 30 21:26:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050925, encodeId=2af92050925e5, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 17 12:26:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700043, encodeId=7b341e0004365, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Thu Apr 12 16:26:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757892, encodeId=d3db1e5789297, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Aug 27 09:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256612, encodeId=3d1d1256612ba, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 17 01:26:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

患者突然死亡,家属却向医务人员致谢!

从患者突然出现情况到实施抢救,时间不超过一分钟,抢救时间超过两个小时,抢救措施完备,家属无可挑剔。

暖!患者突然心脏骤停,黑龙江几位医生跪地40分钟抢救

一名等待心电检查的七旬男性患者突然心脏骤停,经过医护人员整整40分钟的心肺复苏施救,患者终于恢复了心跳,有了自主呼吸。

Anesth Analg:罗哌卡因和左旋布比卡因引起大鼠心跳骤停后的恢复:脂肪乳剂的对比研究

脂肪乳剂常用于治疗局麻药引起的心跳骤停。为了研究脂肪乳剂复苏在治疗局部麻醉诱导的心跳骤停中是否受亲脂性的影响,我们比较了脂肪乳剂治疗左旋布比卡因(高亲脂性)和罗哌卡因(较低亲脂性)引起的大鼠心脏骤停模型的效果。

Resuscitation:院内心脏骤停儿童:肾上腺素给药间隔多久为宜?

2017年8月,发表在《Resuscitation》的一项由美国科学家进行的研究考察了儿童院内心脏骤停时,肾上腺素给药间隔和生存结局。

医学奇迹!产妇心脏骤停1小时,母子抢救成功

8月19日,北京朝阳医院医护工作者演绎了一场将一名高龄孕妇和女婴从鬼门关上拉回来的生命奇迹!

盘点:心脏骤停近期重要研究进展汇总

心脏骤停(cardiac arrest, CA)是全世界成人死亡的主要原因之一,每年罹患数百万人。及时有效的心肺复苏(cardiopulmonary resuscitation, CPR)是其唯一救治措施,但救治成功率低,出院存活率 <7%,神经系统损伤是其主要致死和致残原因。这里梅斯小编整理了近期关于心脏骤停的重要研究成果,与大家一同分享。【1】院外心脏骤停后的长期生存情况如何虽然院外心脏骤